Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,477 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Matched Placebo (Capsules) Clear all
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 4 Interventional Results available

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

NCT02410278
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate, montelukast, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
50
States / cities
Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

NCT00356915
View directory record Official record
Conditions
Onychomycosis
Interventions
Itraconazole 100mg capsules, Itraconazole 200mg tablets, Placebo tablets
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
16 Years to 75 Years
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Birmingham, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

NCT06316843
View directory record Official record
Conditions
Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions
Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo
Drug
Lead sponsor
Bateman Horne Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 23, 2026, 3:42 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
El Cajon, California • Murrieta, California • Rialto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 23, 2026, 3:42 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers

NCT07700368
View directory record Official record
Conditions
Healthy Adult
Interventions
L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl)
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 23, 2026, 3:42 PM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 4 Interventional Results available

Adolescent Fibromyalgia Study

NCT01020474
View directory record Official record
Conditions
Fibromyalgia
Interventions
placebo, pregabalin (Lyrica)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
30
States / cities
Los Angeles, California • Santa Ana, California • Delray Beach, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

NCT01007097
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
TAK-875, Glimepiride, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

NCT01280591
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689), DPH 50 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 45 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 23, 2026, 3:42 PM EDT
Withdrawn Phase 2 Interventional

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06834997
View directory record Official record
Conditions
Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions
Dronabinol Capsules, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hosuton, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

Varenicline for Alcohol Dependence

NCT01146613
View directory record Official record
Conditions
Alcoholism
Interventions
Varenicline, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • Bedford, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Results available

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

NCT01044537
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-04937319
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Phoenix, Arizona • Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

NCT00817063
View directory record Official record
Conditions
Eczema
Interventions
alitretinoin, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-6987 for the Treatment of Mild to Moderate Asthma

NCT01296087
View directory record Official record
Conditions
Asthma
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combined Pharmaco/Behavior Therapy in Adolescent Smokers

NCT00330187
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Use Disorder
Interventions
Bupropion SR, Contingency Management, Placebo
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 23, 2026, 3:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Ester and Salt (KEAS) in Young Adults

NCT05545501
View directory record Official record
Conditions
Salt; Excess, Hypertension
Interventions
No Salt, No β-OHB, High Salt, No β-OHB, High Salt, High β-OHB
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
19 Years to 39 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

NCT02702388
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Lenvatinib matching placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

NCT01525394
View directory record Official record
Conditions
Refractory Solid Tumors, Lymphomas
Interventions
Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 3:42 PM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 23, 2026, 3:42 PM EDT
Withdrawn Phase 2 Interventional

Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia

NCT02197286
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cholecalciferol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 23, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CNP520, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 23, 2026, 3:42 PM EDT